The ATPAF2 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line, designed for targeted disruption of the ATPAF2 gene. This loss-of-function model eliminates functional ATPAF2 expression across a heterogeneous cell pool, enabling robust investigation of ATP synthase assembly factor dependency. The polyclonal nature captures diverse editing outcomes, providing a realistic population-level phenotypic representation. This product is suited for researchers studying mitochondrial metabolism and oxidative phosphorylation in lung cancer.
The A-549 cell line is a widely used lung adenocarcinoma model, originally derived from a 58-year-old Caucasian male. These epithelial cells are employed in cancer biology and drug metabolism studies due to their well-characterized metabolic and signaling profiles. A-549 cells maintain a functional mitochondrial network and serve as a system to explore mitochondrial dynamics and metabolic adaptations in non-small cell lung cancer. The ATPAF2 knockout variant enables dissection of mitochondrial ATP synthase assembly in this clinically relevant context.
ATPAF2 encodes an essential assembly factor for the F1 catalytic domain of ATP synthase (complex V). It directly interacts with the ATP5A1 and ATP5B subunits, facilitating their proper folding and integration into the complex. ATPAF2 transcription is regulated by PGC-1??, NRF1, and TFAM, connecting it to mitochondrial biogenesis programs. Disruption of ATPAF2 impairs ATP synthase assembly, leading to diminished complex V activity, reduced mitochondrial ATP synthesis, and loss of inner membrane potential. Consequently, cells often upregulate glycolytic flux, mimicking the Warburg effect characteristic of many cancers.
In A-549 lung adenocarcinoma cells, ATPAF2 knockout serves as a controlled system to examine mitochondrial dependency and metabolic reprogramming. These cells typically rely on both oxidative phosphorylation and glycolysis, and the balance between these pathways influences proliferation and drug response. The knockout allows direct interrogation of how loss of complex V assembly impacts cellular energetics, proliferation, and survival under nutrient limitation or therapeutic stress. By favoring glycolytic metabolism, this model provides a platform to identify synthetic lethality relationships and therapeutic vulnerabilities associated with mitochondrial dysfunction in cancer.
Key applications include Seahorse metabolic flux analysis of oxygen consumption and extracellular acidification, ATP bioluminescence quantification, and mitochondrial membrane potential assays with JC-1 or TMRM. Users may also employ western blotting for complex V subunits, enzymatic activity measurements, and cell viability tests under galactose or oxidative stress to assess mitochondrial competence. These polyclonal cells are valuable for screening metabolic inhibitors, investigating retrograde signaling, and exploring the intersection of mitochondrial impairment and oncogenic pathways. For further technical information, please contact Ascent Research.
